Similar to our earlier findings in sporadic breast cancers, increased RAD21 expression in BRCA2 and BRCAX cancers confers a poor prognosis and resistance to DNA-damaging chemotherapeutic agents. The gene discussed is BRCA2; the disease is breast cancer.